An “X waiver” refers to the Drug Addiction Treatment Act (DATA 2000) “waiver” legislation that authorized the outpatient use of buprenorphine for the treatment of opioid use disorder. This waiver, along with the associated 8 hour (physician) or 24 hour (APP) training was previously required for any provider prescribing buprenorphine.
Beginning January 12, 2023, prescriptions for buprenorphine only require a standard DEA registration number. The X waiver is no longer required for any prescriber to treat patients with buprenorphine for opioid use disorder. There are also no longer any limits or patient caps on the number of patients a prescriber may treat for opioid use disorder with buprenorphine. Read the DEA letter here.
Congress also passed a mandate requiring new DEA applicants or with DEA renewal to take 8 hours of training as a one time education effective June 2023. The existing X waiver training fulfills this criteria. However, if you already completed your X waiver training, you will NOT need to complete this training in the future. Penn is hosting new trainings in February 2023.
Yes! Pharmacies have adapted their practices and PennChart is being updated to remove the X number requirement.
You can watch this short guidance video.
Yes, there are no longer monthly caps or limits for providers for buprenorphine prescriptions.
No! There is a NEW requirement to complete 8 hours of controlled substance prescribing that will be required with your next DEA renewal. The great news is that your X waiver will count for that (once in a lifetime mandated) training.
Anyone who is still interested in completing their X waiver, knowing some training will still be necessary—you are in luck. We are hosting 3 health system trainings later in January and February.